Allosteric modulators of the hERG K+ channel. Radioligand binding assays reveal allosteric characteristics of dofetilide analogs.

Toxicology and Applied Pharmacology

Volumn 274, Issue 1, 2014, Pages 78-86

  Yu, Zhiyi ^a   Klaasse, Elisabeth ^a   Heitman, Laura H ^a   IJzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

3H astemizole; 3H dofetilide; Allosteric modulator; HERG K+ channel; LUF6200; Potassium ions

Indexed keywords

ASTEMIZOLE; DOFETILIDE; POTASSIUM CHANNEL HERG; POTASSIUM ION; RADIOLIGAND; TERFENADINE;

ALLOSTERISM; ARTICLE; BINDING ASSAY; CELL STRAIN HEK293; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG EFFECT; HEART PROARRHYTHMIA; HUMAN; HUMAN CELL;

EID: 84889595195     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.10.024     Document Type: Article

References (51)

1. Almilaji A., Munoz C., Elvira B., Fajol A., Pakladok T., Honisch S., Shumilina E., Lang F., Föller M. AMP-activated protein kinase regulates hERG potassium channel. Pflugers Arch. Eur. J. Physiol 2013, 10.1007/s00424-013-1299-8.
2. + channel. Circ. Res. 1993, 72:707-714.
3. Chen F., Larsen M.B., Neubauer H.A., Sánchez C., Plenge P., Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J. Neurochem. 2005, 92:21-28.
4. + channels. J. Pharmacol. Sci. 2004, 95:311-319.
5. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 2002, 1:198-210.
6. + channel correlate with occupancy of the pore. Biophys. J. 1992, 61:639-648.
7. o. J. Pharmacol. Toxicol. Methods 2004, 50:187-199.
8. 3H] dofetilide binding to guinea pig myocytes. Circ. Res. 1995, 77:718-725.
9. 3H] dofetilide binding to cardiac myocytes: modulation by extracellular potassium. J. Mol. Cell. Cardiol. 1997, 29:183-191.
10. Elinder F., Århem P. Metal ion effects on ion channel gating. Q. Rev. Biophys. 2003, 36:373-427.
11. Fernandez D., Ghanta A., Kauffman G.W., Sanguinetti M.C. Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. 2004, 279:10120-10127.
12. + channel?. Eur. J. Pharmacol. 2001, 412:203-212.
13. Finlayson K., Witchel H.J., McCulloch J., Sharkey J. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. 2004, 500:129-142.
14. Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol. Ther. 2011, 129:109-119.
15. Hancox J.C., McPate M.J., El Harchi A., Zhang Y.h. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 2008, 119:118-132.
16. 3H] Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor. Mol. Pharmacol. 2008, 73:518-524.
17. Heitman L.H., Ye K., Oosterom J., IJzerman A.P. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol. Pharmacol. 2008, 73:1808-1815.
18. Hogg R.C., Buisson B., Bertrand D. Allosteric modulation of ligand-gated ion channels. Biochem. Pharmacol. 2005, 70:1267-1276.
19. Hoppe U.C., Marbán E., Johns D.C. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5335-5340.
20. IJzerman A.P., Wijngaarden I.v, Soudijn W. Allosteric modulation of G-protein-coupled receptors. Expert Opin. Ther. Pat. 2001, 11:1889-1904.
21. Kamiya K., Niwa R., Mitcheson J.S., Sanguinetti M.C. Molecular determinants of HERG channel block. Mol. Pharmacol. 2006, 69:1709-1716.
22. Keating M.T., Sanguinetti M.C. Molecular and cellular mechanisms review of cardiac arrhythmias. Cell 2001, 104:569-580.
23. Lees-Miller J.P., Duan Y., Teng G.Q., Duff H.J. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. 2000, 57:367-374.
24. Liu X., Limberis J.T., Su Z., Houseman K., Diaz G.J., Gintant G.A., Cox B.F., Martin R.L. Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. Life Sci. 2012, 90:607-611.
25. May L.T., Leach K., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47:1-51.
26. 7 receptor. Br. J. Pharmacol. 2008, 153:737-750.
27. 7 receptor that contribute to human and rat species differences in antagonist effects. Br. J. Pharmacol. 2008, 155:738-751.
28. Milnes J.T., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. 2003, 139:887-898.
29. Milnes J.T., Dempsey C.E., Ridley J.M., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett. 2003, 547:20-26.
30. Mitcheson J.S. Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine. Br. J. Pharmacol. 2003, 139:883-884.
31. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12329-12333.
32. Ng C.A., Hunter M.J., Perry M.D., Mobli M., Ke Y., Kuchel P.W., King G.F., Stock D., Vandenberg J.I. The N-terminal tail of hERG contains an amphipathic α-helix that regulates channel deactivation. PLoS One 2011, 6:e16191.
33. + conductance. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20075-20080.
34. Perry M., Sanguinetti M., Mitcheson J. Symposium review: revealing the structural basis of action of hERG potassium channel activators and blockers. J. Physiol. 2010, 588:3157-3167.
35. 2+ but is independent of modulation by spermidine. Neurochem. Res. 2004, 29:819-825.
36. Sancar F., Czajkowski C. Allosteric modulators induce distinct movements at the GABA-binding site interface of the GABA-A receptor. Neuropharmacology 2011, 60:520-528.
37. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26:119-124.
38. Sanguinetti M.C., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469.
39. Schetz J.A., Sibley D.R. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J. Pharmacol. Exp. Ther. 2001, 296:359-363.
40. Schönherr R., Heinemann S.H. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J. Physiol. 1996, 493:635-642.
41. + channel blockade by synthesis and biological evaluation of dofetilide analogues. ChemMedChem 2009, 4:1722-1732.
42. Smith P., Krohn R.I., Hermanson G., Mallia A., Gartner F., Provenzano M., Fujimoto E., Goeke N., Olson B., Klenk D. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
43. Trattnig S.M., Harpsøe K., Thygesen S.B., Rahr L.M., Ahring P.K., Balle T., Jensen A.A. Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site. J. Biol. Chem. 2012, 287:25241-25254.
44. Uebele V.N., Nuss C.E., Fox S.V., Garson S.L., Cristescu R., Doran S.M., Kraus R.L., Santarelli V.P., Li Y., Barrow J.C. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem. Biophys. 2009, 55:81-93.
45. + channels: friend and foe. Trends Pharmacol. Sci. 2001, 22:240-246.
46. Vargas H.M., Bass A.S., Breidenbach A., Feldman H.S., Gintant G.A., Harmer A.R., Heath B., Hoffmann P., Lagrutta A., Leishman D. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J. Pharmacol. Toxicol. Methods 2008, 58:72-76.
47. + channels. J. Gen. Physiol. 2003, 121:583-598.
48. Yoshimura R.F., Hogenkamp D.J., Li W.Y., Tran M.B., Belluzzi J.D., Whittemore E.R., Leslie F.M., Gee K.W. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J. Pharmacol. Exp. Ther. 2007, 323:907-915.
49. Zhou J., Augelli-Szafran C.E., Bradley J.A., Chen X., Koci B.J., Volberg W.A., Sun Z., Cordes J.S. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 2005, 68:876-884.
50. Zhou P.-z, Babcock J., Liu L.-q, Li M., Gao Z.-b Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules. Acta Pharmacol. Sin. 2011, 32:781-788.
51. Zünkler B., Friemel A. Allosteric interactions between terfenadine and chlorobutanol on hERG channels. Toxicol. Lett. 2009, 189:S257.